This study is accepting new patients by invitation only
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Summary
- Eligibility
- for people ages 18-100 (full criteria)
- Location
- at UCLA
- Dates
- study startedcompletion around
Description
Summary
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients by invitation only
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Rigel Pharmaceuticals
- ID
- NCT04138927
- Phase
- Phase 3 Anemia Research Study
- Study Type
- Interventional
- Participants
- Expecting 90 study participants
- Last Updated